in

Nestle Pays $2 Billion to Secure Aimmune’s Allergy Treatment

Vevey, Switzerland, August 31 2020 (CNBC) — Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business. Known for its KitKat chocolate bars and Nescafe instant coffee, Nestle set up Nestle Health Science (NHS) in 2011 to open up a new area of business between food and pharma.

https://www.cnbc.com/2020/08/31/nestle-to-buy-aimmune-therapeutics-for-2point6-billion.html

What do you think?

Written by hsandm

Former SVP and President for Walmart Health Pivots to Modernize the Testing Industry

Danaher Appoints Rainer M. Blair as President and CEO